Bicara Therapeutics (NASDAQ:BCAX) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of Bicara Therapeutics (NASDAQ:BCAX - Free Report) in a research report released on Friday, MarketBeat reports. The brokerage issued a buy rating and a $42.00 price target on the stock.

A number of other brokerages have also recently issued reports on BCAX. Stifel Nicolaus started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price objective for the company. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an "overweight" rating for the company. Morgan Stanley began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price on the stock. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $43.00.

Bicara Therapeutics Stock Up 8.0 %

NASDAQ:BCAX traded up $1.56 during mid-day trading on Friday, hitting $21.10. The company's stock had a trading volume of 307,299 shares, compared to its average volume of 293,732. Bicara Therapeutics has a fifty-two week low of $17.41 and a fifty-two week high of $28.09. The company has a fifty day simple moving average of $21.73.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). On average, research analysts expect that Bicara Therapeutics will post -2.89 EPS for the current year.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the stock in a transaction on Monday, September 16th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares in the company, valued at approximately $77,461,524. This trade represents a 74.20 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder James E. Flynn purchased 70,000 shares of the company's stock in a transaction on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the purchase, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 8.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds have recently made changes to their positions in the business. First Turn Management LLC bought a new position in Bicara Therapeutics in the third quarter valued at $14,324,000. Vestal Point Capital LP acquired a new stake in shares of Bicara Therapeutics in the third quarter valued at about $10,825,000. Braidwell LP acquired a new stake in shares of Bicara Therapeutics in the third quarter valued at about $42,219,000. FMR LLC bought a new stake in Bicara Therapeutics during the third quarter worth about $57,913,000. Finally, Point72 DIFC Ltd bought a new position in Bicara Therapeutics in the third quarter valued at approximately $1,420,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.